Draft:Andrew Allen

Submission declined on 19 July 2026 by Scope creep (talk). This draft's references do not show that the person meets Wikipedia's criteria for inclusion for people. The draft requires multiple published secondary sources that: provide significant coverage: discuss the person in detail, not brief mentions or interviews lacking independent analysis; are reliable: from reputable outlets with editorial oversight; are independent: not connected to the person, such as interviews, press releases, the subject's own website, or sponsored content. Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by Scope creep 37 days ago. Last edited by Scope creep 37 days ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

Andrew Allen, M.D., Ph.D. is a physician-scientist and biotechnology entrepreneur who has played a role in the development of multiple oncology therapeutics.

Allen trained in medicine at the University of Oxford and earned a Ph.D. in immunology from Imperial College London.^[1][2]

Allen began his biotechnology career in oncology drug development roles at Abbott Laboratories and Chiron Corporation. In 2006 he joined Pharmion Corporation as Chief Medical Officer, where he helped lead the clinical development of Azacitidine, a DNA methylation inhibitor used for the treatment of myelodysplastic syndromes.^[3]

In 2009, Allen co-founded Clovis Oncology, where he served as Chief Medical Officer until 2015. During his tenure, the company developed Rucaparib, a PARP inhibitor later approved for ovarian and prostate cancers.^[4][5]

In 2015, Allen co-founded Gritstone bio and served as chief executive officer, which developed neoantigen vaccines.^[1]

Allen has also served on the boards of multiple biotechnology companies.^[1]

Allen has contributed to the development of targeted therapies and personalized immunotherapy approaches in oncology. Allen's scientific contributions include advancing the translational science of neoantigen vaccines. In 2024, he co-authored a study in Nature Medicine analyzing samples from a Gritstone-led clinical trial, which revealed an unexpected hierarchy of neoantigen immunodominance in which T-cell responses preferentially focused on TP53-derived epitopes at the expense of clinically relevant KRAS neoantigens.^[6] The study demonstrated how dominant epitopes within a multi-epitope construct can suppress immune responses to other encoded targets, helping establish broader principles of antigen competition in therapeutic cancer vaccines.